Savient Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 8 of about 8   

Articles published

SVNTQ 0.0070 +0.0008 (12.90%)
price chart
NephroGenex, Inc. Reports Year-End 2013 Financial Results
Mr. Hamill previously served as Co-President and CFO of Savient Pharmaceuticals, Inc., EVP and CFO of PharmaNet Development Group Inc. and CFO of PharmaNet, Inc. Entered into a manufacturing agreement with Patheon Pharmaceuticals Inc. for clinical ...
Related articles »  
Elusys Completes Commercial Manufacturing Process Validation for Anthrax ...
PINE BROOK, N.J., April 8, 2014 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, today announced that it has completed validation of the commercial manufacturing ...
Related articles »  
Savient Pharmaceuticals Inc Names John P. Hamill CFO
Savient Pharmaceuticals Inc Announces CEO Appointment